SOLUTIONS > OUR DATABANK
OUR DATABANK
PERSONALIZE MY TREATMENT
Personalize My Treatment (PMT) is an REB-approved active pan-Canadian oncology databank that captures clinical and biomarker data for pharmaceutical, clinical, regulatory and payer decision-makers who are looking for analytics-based insights and real-world evidence to improve patient outcomes.
HOW IT WORKS
Our enrollment strategy focuses on all stages of molecularly profiled cancer patients. Consented patients are followed throughout their disease trajectory and can be re-contacted if they are eligible to participate in clinical trials. Uniquely, our initiative allows a standardized and structured network-wide longitudinal patient collection of real-world data (RWD) from patients’ medical records. It also avoids the bias and risks of combining unstructured data collection from multiple technology architectures and sources.
The PMT databank is presently active at 16 cancer centres across Canada in our network. At each Exactis Network site, dedicated PMT Coordinators enrol participants, collect de-identified real-world data from medical records, facilitate biospecimen collection, assist in the return of results and patient re-contact for study participation.
Patients participating in the PMT databank, consent to:
- Having their longitudinal clinical and molecular data collected;
- Sharing their biospecimens for profiling and analysis;
- Being re-contacted if they become eligible for a clinical trial or an approved therapy, based on the characteristics of their cancer;
- Being followed through their disease trajectory.
ACCESS TO BIOSPECIMENS
The fundamental component of precision oncology is the capture of biomarkers and molecular signatures enabling patient matching to precision medicines. PMT participants consent not only to share their medical information, but also their biospecimens (archived tissues and blood samples) and medical images for further research projects and analyses. Exactis can identify specific patient populations of interest across the network and has a coordinated approach to hospital biobanks and pathology departments so patients’ samples can be rapidly collected and procurement efficiently performed.
WHY TRUST EXACTIS
Exactis is an impartial, non-affiliated, and not-for-profit organization, making it a trusted partner amongst oncologists, government decision makers, and industry leaders when it comes to making better patient cancer care decisions. Exactis is also a Business-Led Networks Centres of Excellence (BL-NCE) and a Network Collaborator for the Canadian Agency for Drugs & Technologies in Health (CADTH) Post-market Drug Evaluation (PMDE) Program.
Our longitudinal PMT cancer databank is a high quality, structured dataset that guarantees patients’ confidentiality, data privacy, and security and benefits from a REB-approved approach and transparent governance.
Our PMT databank is based on the mCODE (Minimal Common Oncology Data Elements) initiative for its data architecture and variables. The de-identified data in the PMT databank meet the following key criteria:
PRIVACY
Exactis follows the highest Canadian standards for privacy. Patients are de-identified at source with a unique PMT ID assigned to all clinical data in the PMT database.
STANDARDIZED
Use of common international data dictionaries for compatibility, common guidelines for data entry, monitoring, and absence of free text.
COMPUTABLE
Format allowing the use of statistical functions like summary, average, median, survival, etc.
CLINICALLY APPLICABLE
Variables suitable for generation of real world insights in oncology.